pregabalin (Lyrica)

07/01/2014 - "Pregabalin ≥ 300 mg/day was most effective for ≥ 30% and ≥ 50% pain reduction [relative risk (RR) vs. placebo = 2.44 and 2.13, respectively]. "
11/01/2010 - "Path-analysis showed that most of the pain relief observed with pregabalin treatment was a direct analgesic effect and was not explained by improvement in mood. "
05/01/2015 - "In both trials, significant improvement of pain and pain-related sleep interference occurred within 2 days of initiating treatment with pregabalin. "
01/01/2012 - "If the results from this study could be adapted to clinical settings, the combination of WIN with pregabalin might be beneficial for pain relief in humans."
11/01/2010 - "In seven of the nine trials (representing 11 of 14 pregabalin arms), significant reduction in pain was achieved at end point. "

11/01/2007 - "Although pregabalin shows efficacy against neuropathic pain, very limited evidence supports postoperative analgesic efficacy. "
01/01/2012 - "Although pregabalin therapy is beneficial for neuropathic pain (NeP) by targeting the CaVα2δ-1 subunit, its site of action is uncertain. "
11/01/2008 - "These results suggest that pregabalin may be beneficial in patients with neuropathic pain who have had an unsatisfactory response to treatment with other medications."
01/01/2015 - "Pregabalin is a commonly used therapy currently recommended as first-line treatment for a number of neuropathic pain (NeP) conditions. "
08/01/2010 - "Flexible-dose pregabalin 150-600 mg/day was effective in relieving neuropathic pain, improving disturbed sleep, improving overall patient status, and was generally well tolerated in patients with post-traumatic peripheral neuropathic pain."

03/01/2012 - "Although pregabalin has demonstrated efficacy in the treatment of generalized anxiety disorder (GAD) in a number of randomized controlled trials, there is little published data on the optimal dose for treating this condition. "
02/01/2004 - "High dose pregabalin is effective for the treatment of generalised anxiety disorder."
04/01/2005 - "This study demonstrates that pregabalin is an effective treatment of generalized anxiety disorder, with BID dosing showing similar efficacy and comparable tolerability with TID dosing."
04/01/2004 - "In conclusion, pregabalin 600 mg/d was an effective and well-tolerated treatment of social anxiety disorder."
03/01/2003 - "These results indicate that pregabalin is an effective, rapidly acting, and safe treatment for generalized anxiety disorder. "

07/01/2015 - "Pregabalin significantly improved Hospital Anxiety and Depression Scale-Anxiety (difference -0.95, p < 0.0001) and -Depression (difference -0.88, p = 0.0005) scores, Fibromyalgia Impact Questionnaire total score (difference -6.60, p < 0.0001), and sleep quality (difference 0.57, p < 0.0001), but not EuroQol 5-Dimensions score (difference 0.02, p = 0.3854). "
10/01/2014 - "Time to LTR was significantly longer with pregabalin CR versus placebo in fibromyalgia patients who initially showed improvement with pregabalin CR, indicating maintenance of response. "
01/01/2010 - "These results suggest that pregabalin may be beneficial in patients with fibromyalgia who have had an unsatisfactory response to treatment with other medications."
07/01/2010 - "For PGIC, administration of pregabalin resulted in an increase in the proportion of patients reporting improvement with an ED50 of 228 mg. The analyses support the recommended dose of pregabalin in patients with fibromyalgia of 300 to 450 mg/d."
01/01/2008 - "Pregabalin is, therefore, a valuable option in the first-line treatment of patients with fibromyalgia."

02/16/2006 - "In well-done clinical trials, pregabalin 150-600 mg/day has been shown to be highly effective and well tolerated as adjunctive therapy in patients with partial seizures. "
11/01/2011 - "Pregabalin treatment was associated with a significant reduction in partial seizure frequency: median percent change in partial seizure frequency from baseline to 12 weeks was -33% and -22% in patients with a baseline seizure frequency of ≤3 and >3 per 28 days, respectively. "
08/01/2009 - "A significantly greater proportion of patients were free of seizures in the combined pregabalin 150-600 mg/day and the pregabalin 600 mg/day fixed-dosage groups compared with the placebo groups from treatment day 2 onward (p < 0.05). "
11/01/2008 - "A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P=0.0005). "
05/16/2005 - "At the highest dose, mean seizure reduction for pregabalin was 44.3 to 54%, a significant reduction compared to placebo (p < or =0.0001), and a response rate of 43.5 to 51% (p < or =0.001). "